EN
TR
Adverse Cardiac Effects Of Decongestants Agents
Abstract
Especially in spring and winter months many people use excessive dose topical or systemic decongestant agents to relief the allergic or infectious nasal congestive symptoms without physicians\' prescription. Although these agents bring some symptomatic benefits, sometimes serious adverse cardiac events reported at all drug users, especially who had known cardiac disease. These agents may cause slightly elevation of blood pressure in hypertensive patients, can trigger mortal arrhythmias like ventricular tachycardia, can also trigger myocardial infarction patients with known coronary artery disease or normal coronary artery and may cause decompensation of heart failure. In conclusion all these decongestant agents give only symptomatic relief and they don\'t treat flu and allergic disease. For this reason if the symptoms are mild or moderate not using these agents will be more wisely.
Keywords
References
- American Academy of Allergy, Asthma and Immunology. The Allergy Report. Available at: http://www.thealler- gyreport.org/reportindex.html. Accessed April 2, 2002
- Dollery C, ed. Therapeutic Drugs, 2nd edn. Edinburgh: Churchill Livingstone 1999
- International Conference on Allergic Rhinitis in Childhood. Allergy 1999;54(suppl 55):7-34
- Pentel P. Toxicity of over-the-counter stimulants. JAMA. 1984; 252:1898-1903/ Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attrbuted to phenylpro- panolamine: a review of 142 case reports. Am J Med 1990;89:195-208
- Radack K, Deck CC. Are oral decongestants safe in hyper- tension? An evaluation of the evidence and framework for assessing clinical trials. Ann Allergy 1986;56:396-401
- Morgan JP, Funderburk FR. Phenylpropanolamine and blood pressure:a review of prospective studies. Am J Clin Nutr 1992:55(supp)206S-10S
- Stephan M.S, Jeffrey L.J, Elizabeth P.B. Effect of oral pseudoephedrine on blood pressure and heart rate. Arch Intern Med 2005;165:1686-94
- US Food and Drug Administration. Center for Drug Evaluation and Resarch: phenylpropanolamine (PPA)page. Availableat:http//www.fda.gov/cder/drug/infopage/ ppa/default.htm. Accessed Dcember15, 2003
Details
Primary Language
English
Subjects
-
Journal Section
-
Publication Date
March 21, 2016
Submission Date
April 27, 2015
Acceptance Date
-
Published in Issue
Year 2013 Volume: 10 Number: 12
APA
Kaya, Z., & Tuncez, A. (2016). Adverse Cardiac Effects Of Decongestants Agents. European Journal of General Medicine, 10(12). https://izlik.org/JA85LA77XU
AMA
1.Kaya Z, Tuncez A. Adverse Cardiac Effects Of Decongestants Agents. European Journal of General Medicine. 2016;10(12). https://izlik.org/JA85LA77XU
Chicago
Kaya, Zeynettin, and Abdullah Tuncez. 2016. “Adverse Cardiac Effects Of Decongestants Agents”. European Journal of General Medicine 10 (12). https://izlik.org/JA85LA77XU.
EndNote
Kaya Z, Tuncez A (March 1, 2016) Adverse Cardiac Effects Of Decongestants Agents. European Journal of General Medicine 10 12
IEEE
[1]Z. Kaya and A. Tuncez, “Adverse Cardiac Effects Of Decongestants Agents”, European Journal of General Medicine, vol. 10, no. 12, Mar. 2016, [Online]. Available: https://izlik.org/JA85LA77XU
ISNAD
Kaya, Zeynettin - Tuncez, Abdullah. “Adverse Cardiac Effects Of Decongestants Agents”. European Journal of General Medicine 10/12 (March 1, 2016). https://izlik.org/JA85LA77XU.
JAMA
1.Kaya Z, Tuncez A. Adverse Cardiac Effects Of Decongestants Agents. European Journal of General Medicine. 2016;10. Available at https://izlik.org/JA85LA77XU.
MLA
Kaya, Zeynettin, and Abdullah Tuncez. “Adverse Cardiac Effects Of Decongestants Agents”. European Journal of General Medicine, vol. 10, no. 12, Mar. 2016, https://izlik.org/JA85LA77XU.
Vancouver
1.Zeynettin Kaya, Abdullah Tuncez. Adverse Cardiac Effects Of Decongestants Agents. European Journal of General Medicine [Internet]. 2016 Mar. 1;10(12). Available from: https://izlik.org/JA85LA77XU